Breast Cancer
A Randomized, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer
Trial ID: 08225
Contact: Sharon S Ambro
Phone: (972)841-8345
Learn More about this trial.
go back | new search